drug
VIR-5500
Phase 1updated 6mo agoby $VIR Vir Biotechnology, Inc.
Phase 1community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying VIR-5500
News(4)
- Vir's hepatitis delta combo tamps down virus as Gilead showdown loomsVir Biotechnology is targeting a mid-2027 regulatory submission for its monthly chronic hepatitis delta regimen, with head-to-head data against Gilead’s Hepcludex expected next quarter.biospace · 9d ago
- Astellas bets up to $1.34B for option to advance Audax immuno-oncology assetAstellas Pharma could secure the exclusive global rights to Audax Biosciences’ DAX-044, an antibody-cytokine fusion therapy that activates the immune system in the vicinity of the tumor.biospace · 22d ago
- Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagersThe Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tu…biospace · 1mo ago
- Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEsLooking to expand its oncology portfolio, Gilead has tapped Vir Biotechnology’s masked T-cell engager tech in a potential $1.9 billion biobucks deal.fiercebiotech · 1mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that